• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CGB 9.09% 0.5¢

CANN GLOBAL LIMITED - Corporate Spotlight

Cann Global Limited is a driving force in the medical Cannabis industry. Our strength... Cann Global Limited is a driving force in the medical Cannabis industry. Our strength comes from our team’s core competencies and expertise and our solid and strategic partnerships with experts in Australia, Israel and Canada. We believe in building a stronger industry together.More

Corporate Spotlight

Cann Global Limited is a driving force in the medical Cannabis industry. Our strength comes from our team’s core competencies and expertise and our solid and strategic partnerships with experts in Australia, Israel and Canada. We believe in building a stronger industry together.
View the full Corporate Spotlight arrow Created with Sketch.

EXPORT PERMIT GRANTED FOR CANNTAB'S HARD PILL

EXPORT PERMIT GRANTED FOR CANNTAB'S PILL

arrow-down-2 Created with Sketch.


Cann Global (ASX:CGB) begins importing Canntab cannabis pills to Australia

Health Care

ASX:CGB    

  • Cann Global's (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia

  • Canntab Therapeutics has been given the green light by Health Canada, meaning Cann Global can begin importing the products
  • The patented pills from Canntab are unique as they allow for precise dosing
  • CGB plans to order six different products from the pill range
  • Among the pills Cann Global has ordered are two THC products, two CBD products and two THC/CBD blends
  • The products will begin arriving in Australia next month and will be available through the Special Access Scheme B and Authorised Prescriber schemes

Cann Global's (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia.


Canntab Therapeutics has been given the green light by Health Canada, while Cann Global has already secured the necessary import permits for the pills.


Following the export permit being issued, Cann advises that its order of the hard pill products will begin arriving in Australia next month.


Canntab's products are unique because of the patented hard pill form which they come in, which allows for more precise dosing.


CGB has ordered six different products from its JV partner, including two THC products, two CBD products and two THC/CBD blends.


The CBD and THC pills will be available in Australia through both the Special Access Scheme B and Authorised prescriber schemes. 


Cann is also planning to make the pills available to the Cannabinoid Medicine Observational Study (CMOS) which is testing the efficacy of cannabis on neurological and mental health conditions.


Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share at 10:06 am AEDT.


Read the full article on The Market Herald here.

CGB VENTURE PARTNER GRANTED AUS PATENT

arrow-down-2 Created with Sketch.

Cann Global’s (ASX:CGB) joint venture partner granted Australian patent

Health Care

ASX:CGB   
Cann Global (ASX:CGB): Disrupting the lucrative Australian cannabis market
Source: Cann Global

  • Cann Global's (CGB) joint venture partner, Canntab Therapeutics, has been granted an Australian patent in relation to its proprietary immediate release cannabidiol formulations
  • The partners formed a 50:50 joint venture in 2018 to bring Canntab's range of hard oral dose cannabinoid tablets to Australia 
  • Cann Global has placed an initial C$406,200 (approximately A$418,000) order for six products which will be filled when Cantabb receives an export permit 
  • Once the products arrive in the country, the range will be made available through the Special Access Scheme B, Authorised prescriber schemes as well as the Cannabinoid Medicine Observational Study
  • CGB shares are up 6.25 per cent to 0.9 cents

Cann Global's (CGB) Canada-based joint venture partner, Canntab Therapeutics, has been granted an Australian patent. 


The patent, No. AU 2018210690, was granted in relations to Canntab's proprietary immediate release cannabidiol formulations. The patent has a priority date of January 23, 2017, and expires on January 22, 2038. 


Cann Global and Canntab formed a 50:50 joint venture partnership in 2018 with the objective of bringing a range of hard pill cannabinoid formulations to Australia. 


Once the products arrive in the country, the range will be made available through the Special Access Scheme B, Authorised prescriber schemes as well as the Cannabinoid Medicine Observational Study (CMOS). 


The study is the largest observational study for cannabinoid medicines undertaken to date in the country and will evaluate the safety and efficacy of medicinal cannabis products. 


The CMOS aims to enrol 20,000 patients with conditions such as fibromyalgia, chronic pain syndromes, PTSD and epilepsy and will collect data on health-related outcomes. 


Cann Global has already placed an initial C$406,200 (approximately A$418,000) order for six products from the Canntab range: two THC products, two CBD products and two THC/CBD blends. 


Cann Global has received an import permit for the products, while Canntab awaits an export permit from Health Canada. 

CGB shares are up 6.25 per cent to 0.9 cents at 10:26 am AEDT.


Read the full article on The Market Herald here.

CGB RISE AS THAILAND HEMP RULES CHANGE

arrow-down-2 Created with Sketch.

Cann Global (ASX:CGB) shares on the rise after Thailand’s hemp rules change

Health Care

ASX:CGB    
Cann Global (ASX:CGB) shares on the rise after Thailand’s hemp rules change


  • Cann Global (CGB) shares are on the rise today after the Thailand Government changed regulations for hemp 
  • From Friday, January 29, the Thailand Government will begin processing applications for hemp licences 
  • Prior to the changes, hemp licences were only issued to those undertaking research programs in Thailand
  • Cann's subsidiary, Cann Global Thailand, is expected to benefit from the new regulations and will be able to offer its services to multiple companies



Cann Global (CGB) shares are on the rise today after Thailand's regulation for hemp changes. 


From Friday, January 29, the Thailand Government will begin processing applications for licences to produce, import, export, distribute and possess hemp. 


This is a significant step for Thailand's hemp industry. 


Prior to the changes, hemp licences were only issued to those undertaking research programs in Thailand. 


Cann's 55 per cent owned subsidiary, Cann Global Thailand (CGT) has been providing technical support for the last year to AA Bio Co, relating to its hemp cultivation research program with Uttaradit Rajajaht University. 


CGT was created to provide a full cultivation and extraction service for Thai clients. In particular, CGT will provide seeds, organic growing materials, extraction equipment and information technology systems to manage cultivations. 


"We have a full-time expert team in place who have been preparing the groundwork and establishing partnerships and infrastructure to allow CGT to immediately capitalise on these regulatory changes," Managing Director Sholom Feldman said.


"The regulatory changes open the market up significantly to benefit CGT’s service-based revenue model and we look forward to maximising the value of our first-mover status in this large new market," he added.


Read the full article on The Market Herald here.

CGB DISRUPTING LUCRATIVE CANNABIS MARKET

arrow-down-2 Created with Sketch.

Cann Global (ASX:CGB): Disrupting the lucrative Australian cannabis market

Sponsored

Cann Global (ASX:CGB): Disrupting the lucrative Australian cannabis market
Source: Cann Global


  • The Australian cannabis and hemp industries have largely taken a back seat in 2020 as COVID-19 thrust commodities and tech stocks into the spotlight
  • However, recent changes to TGA's Poisons Standard for cannabidiol products has turned investors' heads to the lucrative plant once more
  • Cann Global has already built up a solid cannabis-based product range and is about to launch hemp-based skincare products and medicinal cannabis tablets
  • The company has four key focus areas: food, hemp cultivation and processing, skincare, and medicine
  • Cann Global's products are already available on the shelves and online with major distributors like Woolworths, Amazon, and Costco
  • Now, thanks to a 2018 joint venture deal with Canada-based Canntab Therapeutics, Cann Global will launch its unique medicinal cannabis products in Australia for the first time
  • Cann Global is poised to slide nicely into the slipstream of the Australian cannabis market, which is only getting stronger

The Australian cannabis and hemp industries have largely taken a back seat in 2020 as COVID-19 thrust commodities and tech stocks into the spotlight. 


However, the Australian Therapeutics Goods Administration (TGA) has recently highlighted some upcoming changes to its Poisons Standard for cannabidiol (CBD) products — turning investors' heads to the lucrative product once more.


But a handful of ASX-listed companies have already built up an established market for cannabis products, which is now set to be boosted even further by the TGA regulation shift. 


Among these is cannabis and hemp specialist Cann Global (CGB), which already sells cannabis-based organic wholefoods and is about to launch its hemp-based skincare products and medicinal cannabis tablets.


Who is Cann Global?

Cann Global has four key focus areas: food, hemp cultivation and processing, skincare, and medicine.


Importantly, the company benefits from a vertically integrated business model wherein the entire process of creating a hemp product is taken care of by Cann; from seed to consumer, Cann Global has a hand in the process. 


Moreover, Cann Global's food products are already available overseas on the shelves and online with major distributors like Woolworths, Amazon, and Costco. 


Of course, Australia has largely been playing catch up with the rest of the developed world when it comes to understanding cannabis and the difference between strains of the plant.


Even so, the medicinal cannabis market is relatively immature globally as governments keep strict regulations on the plant. 


Australia's changing cannabis landscape

When the Turnbull government first legalised the plant for medicinal use in 2016, Australia was still leagues behind many other Western countries. For example, some states in the U.S. started legalising the plant for recreational use in 2012. 


Yet, it's important to note that even though the legality of cannabis differs at a state level in the U.S., the plant is still entirely illegal at a federal level. Banks in America will not open accounts to companies involved in cannabis, and even hemp products were only legalised at a federal level very recently. 


In Australia, the plant has slowly been taking ground in terms of legislation, but it still has some ways to go. The Office of Drug Control (ODC) issued Australia's first cultivation licence in 2017, and by 2020 the product could be prescribed by a local GP for pain relief in any Australia state. 


This gives Australia a foot in the door of the global cannabis market, which Grandview estimates will be worth almost US$74 billion (around A$104 million) by 2027. 


But just because its legal doesn't mean it's easy to get. 

Cannabis is still shrouded in stigma, and a general lack of education around medicinal cannabis in the healthcare sector means doctors are very rarely prescribing medicinal cannabis as a treatment. 


As it stands, only 5 per cent of Australian doctors currently prescribe cannabis medication to patients, and even then, only one in ten of these doctors' patients are generally prescribed the drug. 


Moreover, Australians are generally cautious around cannabis products, often due to a simple lack of understanding about the plant, meaning they are often reluctant to ask their GPs for alternative therapies. 


This is part of Cann Global's mission; the company is ready to lead the category by owning the conversation around medical cannabis — shifting it from scepticism to reason and acceptance.


There’s a crucial role for Cann Global and other industry players to play in the health and wellbeing of global citizens.


More than meets the eye

Much of the scepticism around cannabis comes from a limited understanding of the chemicals found in different strains of the plant. 


It's becoming more widely known that there are two main cannabinoids found in cannabis: tetrahydrocannabinol (THC) and cannabidiol (CBD). Generally speaking, THC is responsible for the psychoactive effects of the plant while CBD is responsible for its calming effects. 


Hemp is cannabis with less than 0.3 per cent THC — meaning it does not give any sort of high. 


Yet, Cann Global said there is far more to the plant than these two cannabinoids. In fact, the company explained the cannabis plant produces over 100 different types of cannabinoids, each of which acts on human cannabinoid receptors in different ways. 

This is the basis for Cann's business: unlocking the benefits and subsequent value of cannabis through its diverse product range. 


Cann Global in Australia

Australia is primed to get access to Cann's product range through a joint venture deal with Canada-based Canntab Therapeutics signed in January 2018. 


Under the partnership, Cann Global will launch its unique medicinal cannabis products in Australia for the first time. 


Cann Global has locked in an import permit and already made an initial order for six products out of the Canntab range to be imported for distribution across Australia. The range includes two tetrahydrocannabinol (THC) products, two cannabidiol (CBD)-only and two THC/CBD blends. 


The Australia launch is timed impeccably; as the TGA relax cannabis regulations, more Australians will be exposed to the plant. When this happens, CGB products will be in the spotlight with the Canntab deal. 


CGB in a sturdy peer group

What's more, Cann doesn't need to dedicate time and resources to establishing the Australian cannabis market — the company's ASX-listed peers have already laid the groundwork. 


For example, Althea (AGH) imports and supplies medicinal cannabis products to Australians. The company has a $107 million market cap.


Botanix Pharmaceuticals (BOT) makes synthetic cannabinoid products for dermatology and antimicrobial products. Botanix has a $97 million market cap. 


Cann Group, which received Australia's first-ever cultivation licence, produces a range of medicinal cannabis products and operates in a $95 million market cap. 


The takeaway is this: Cann Global is taking its place in the same arena as these listed cannabis entities and already has established business partnerships and a solid product base. 


Thus, with its manageable market cap of around $25 million, CGB is poised for a growth spurt as soon as its products hit Aussie shelves. From there, the company will slide nicely into the slipstream of the Australian cannabis market, which is only getting stronger. 


It's up to investors, then, to nab their piece of the Australian cannabis pie before it takes off and they miss their chance.


Read the full article on The Market Herald

CGB QUARTERLY ACTIVITES AND CASHFLOW

arrow-down-2 Created with Sketch.


Cann Global (ASX:CGB) Quarterly Activities and Cashflow Report

 

Dear Shareholders,

Cann Global (ASX:CGB) is pleased to present its Q1FY20 Quarterly Cashflow and Activities report here. 

Some Key Highlights from the report are as follows:


  • Cash receipts from customers of $448k are up 59% over the prior corresponding period and up 34% over the prior quarter ($333k) continuing to reflect growth in food division sales and revenue from the Company’s subsidiary, Cann Global Thailand.
  • As at 30 September the Company had a healthy cash balance of $8.9m, an increase over the quarter following completion of the successful rights issue. T12 has launched its latest product, chia-soft-gel oil capsules, as planned with a first order received from major retail chain Costco and this will be available in stores in the coming months.
  • As announced to the ASX on 26 October 2020, Cann Global has received its import permit to bring the Canntab cannabinoid hard pills to Australia with sales expected to commence in Q3 FY21.
  • Cann Global also entered into a Grant Agreement with Applied Cannabis Research to support the Cannabinoid Medicine Observational Study, the largest study ever undertaken in Australia, on hard pill cannabinoid formulations produced by Canntab facilitating early exposure to Australian consumers.
  • Cann Global is close to launching the pilot phase of its 100% plant-based skincare product range with branding and go-to-market plans commencing shortly.
Read the full Quarterly Report Here

Cash receipts from customers of $448K were up 59.4% on the prior corresponding period and 34.5% higher than the prior quarter. This result was driven by increased sales in the food division as well as the first cash receipts from Cann Global Thailand.

Accrued revenue has also significantly increased during the period as a result of increased orders for Cann Global’s product range and contracted services in Asia.

Product manufacturing and operating costs were similar to last quarter, but are expected to increase next quarter as a result of the purchase order for Canntab products in preparation for release for sale to the Australian market and the need for increased inventory for T12 to meet growing demand.

As anticipated advertising and marketing costs have increased to $70k for the quarter as the Company’s FY21 marketing strategy continues to develop go-to-market plans for both the new CannTab therapeutic medical cannabis products, and our 100% plant-based premium skin care ranges.

Administration and corporate costs at $562k have increased as expected due to costs associated with the rights issue. Staff costs have increased, albeit marginally, as additional expertise has been added to the team to support the growth of the business, in particular in the area of sales and marketing.

Whilst cash receipts saw strong growth, net cash used in operating activities was higher this quarter largely reflecting an increase in advertising and marketing costs. Last quarter also benefited from a significant GST refund so excluding this anomaly net cash used was only marginally higher than the last quarter. This operating cash flow trend continues to support managements’ efforts to drive the business towards profitability.

At item 6.1 of the appendix 4C the Company reported aggregate amount to related directors’ fees and directors’ remuneration.

During the quarter the rights issue was successfully undertaken with net proceeds totalling $2,289k after transaction costs. The shortfall of the rights issue was concluded in the current quarter and will be reflected in the next quarter’s cash flow.

Commenting on the placement and conclusion of the offer, Cann Global’s Managing Director Sholom Feldman said: 

“We are very pleased with the level of support for the Company which has been demonstrated by our existing shareholders and are also happy to be welcoming new investors to the register.

We are excited about the growth prospects for the Company and pleased with the
support we have received from investors who share our vision”.

Read the full Quarterly Report Here

CGB TO LAUNCH CANNTAB PRODUCTS

arrow-down-2 Created with Sketch.

Cann Global (ASX:CGB) to launch Canntab products in Australia

Health Care

ASX:CGB    MCAP $22.09M 
  • Cann Global (CGB) is launching six medicinal cannabis products into Australia through its joint venture with Canada-based Canntab Therapeutics
  • The. companies partnered up in January 2018 to import and distribute hard pill cannabinoid formulations throughout Australia 
  • The range includes two tetrahydrocannabinol (THC) products, two cannabidiol (CBD)-only products and two THC/CBD blends
  • On top of the launch, Cann Global has entered an agreement with Applied Cannabis Research (ACR) to provide it with a grant to support the Cannabinoid Medicine Observational Study
  • The study will collect data from 20,000 Australian patients to assess the safety and efficacy of the Canntab products
  • Cann Global's shares have soared 30 per cent on the back of this news, to trade for 0.7 cents

Cann Global (CGB) is set to launch uniquely-formulated medicinal cannabis products under the Canntab range into Australia for the first time.


The launch comes under Cann Global's 50:50 joint venture partnership with Canada-based Canntab Therapeutics. The pair partnered in January 2018 to import and distribute hard pill cannabinoid formulations throughout Australia.


Pleasingly, Cann Global has also confirmed receiving an import permit and an initial order for the products has been made. A total of six products out of the Canntab range are being imported for distribution across Australia.


"We are very excited to progress the launch of CannTab’s innovative cannabis-based tablets in Australia which we expect will be very sought-after by doctors who are looking to prescribe pharmaceutical grade medicinal Cannabis products to their patients," CGB Managing Director Sholom Feldman said.


The range includes two tetrahydrocannabinol (THC) products, two cannabidiol (CBD)-only and two THC/CBD blends.

Further, the CBD products may benefit from the Therapeutic Goods Administration's (TGA) proposed amendment to create a new Schedule 3 entry for CBD. This will allow greater access to CBD products.


In early September, the TGA released a notice regarding the potential amendment to the current Poisons Standard for CBD. The amendment allows Australian patients to buy CBD products after a consultation with a pharmacist without needing a prescription. The TGA has announced June 1, 2021, as the proposed implementation date.


On top of the Australian launch, Cann Global has entered a grant agreement with Applied Cannabis Research (ACR). CGB will provide a grant to ACR to support the Cannabinoid Medicine Observational Study (CMOS) on Canntab's hard pill cannabinoid formulations. 


Under the study, CMOS will collect data from 20,000 patients across the country to assess the safety and efficacy of the products which will be supplied through CGB's joint venture with Canntab.


Significantly, this marks the largest observational study that has ever been undertaken in Australia for medicinal cannabis products. The study will capture data from a broader range of Australian prescribers and patients than in existing studies.


Read the full article on The Market Herald here: https://themarketherald.com.au/cann-global-asxcgb-to-launch-canntab-products-in-australia-2020-10-26/

CGB ENDS BUSY Q4 WITH MONEY IN THE BANK

arrow-down-2 Created with Sketch.

Cann Global (ASX:CGB) ends busy Q4 with $7.4M in the bank

Health Care

ASX:CGB
Cann Global (ASX:CGB) reports sales growth in Australia and Vietnam
  • Cann Global (CGB) has ended the June quarter with a healthy $7.4 million in the bank after burning through $463,000 on operating costs
  • The company also received $333,000 in customer receipts in Q4, an increase of 54.6 per cent compared to the amount received in Q3
  • But Cann's production costs grew by 12.6 per cent in the June quarter, though it did manage to reduce staff costs by 30.5 per cent
  • In terms of activities, the company had a busy quarter finalising its new chia oil and soft-gel capsules
  • Cann also received a Parliamentary green light on hemp certification for its export products
  • While it also received significant results from its trial aimed at stopping the progression of MS via a unique cannabis strain
  • Shares in Cann Global closed worth 0.45 cents on Monday

Cann Global (CGB) has ended a busy June quarter with a healthy $7.4 million in the bank after receiving $545,000 in revenue.


Finances

Of that $545,000, the company received $333,000 in customer receipts, which represents an increase of 54.6 per cent compared to the amount received in Q3.


It's accrued revenue also increased by 42 per cent quarter-on-quarter, while year-on-year it improved by a strong 165 per cent.

Cann burnt through $463,000 on operating costs during the June quarter, with the majority of that going towards staff and admin costs.


However, the company said it had undertaken a review of its staff and admin costs and managed to reduce them by 30.5 per cent in Q4.


Production costs also crept up for Cann in Q4, increasing by 12 per cent to sit at $286,000.

Cann said the rise was due to an increase in inventory, which it undertook in order to secure long-term contracts.

The company also revealed it hopes to be cash-flow positive shortly, as its operating costs trended down over the entire FY20.

Since the end of Q4, Cann has successfully raised $2.2 million in capital via an entitlement offer to top-up its bank balance.


Activities

It was a busy quarter for Cann in terms of activities, as the company spent a few weeks voluntarily suspended from trading, as it geared up for a research announcement.


The announcement is question was that it had recorded positive results from trials aimed at stopping the progression of multiple sclerosis (MS) using a unique strain of cannabis.


The research from the trial shows the particular cannabis strain tested can even reverse the progression of MS.

Along with this update, Cann also spent much of the quarter focused on the development and market introduction of its new Chia Seed Oil and Chia Oil Soft-Gel Capsule.


The products, which fall under Cann's T12 brand, are expected to start being sold during this quarter.

The company also had a win with its hemp products, with a new bill passing in Australian Parliament allowing hemp products to be exported with a key certificate.


This certification is needed in order for the hemp to be legally accepted into some overseas markets, and Cann said the move will allow them to grow their export reach.


Looking ahead, the company's executive chairperson, Pnina Feldman, said the focus was on medicinal cannabis, as its schedule class may soon legally change.


"CGB is well placed to take advantage of these regulatory changes which further strengthens our path to profitability," she said.

Shares in Cann Global closed worth 0.45 cents on Monday.


Read the full article on The Market Herald here: https://themarketherald.com.au/cann-global-asxcgb-ends-busy-q4-with-7-4m-in-the-bank-2020-08-03/

VIDEO

arrow-down-2 Created with Sketch.



CannGlobal's latest Investor Updates with Sholom Feldman, and The Market Herald October 2020

 


Cann Global discuss their latest Annual Report and company results - October 2020





Cann Global 4e Financial Results and Company Progress Updates with Sholom Feldman - August 2020






CGB New COO Appointed - August 2020





ABOUT CANN GLOBAL

arrow-down-2 Created with Sketch.

ABOUT CANN GLOBAL

Visit Cann Global's Website Here


Welcome to Cann Global Limited

Cann Global Limited is a driving force in the medical Cannabis industry. Our strength comes from our team’s core competencies and expertise and our solid and strategic partnerships with experts in Australia, Israel and Canada. We believe in building a stronger industry together. 


We are working under the provision of legislations to ensure that the future in Medical Cannabis and Natural Foods will allow medical practitioners, patients and consumers to gain access to the right information, as well as the safest, most effective and sustainable products. 


Part of our work is to keep researching and educating. We are part of a worldwide movement, the return to Nature. This movement is more than just a phenomenon, it is a necessity. At Cann Global Limited, we are committed to leading a movement, not just a business.


Medical Cannabis

For our Medical Cannabis Division, Cann Global Ltd has established a team of renown experts with experience, knowledge, vision and business astuteness. Our strategy is to leverage the intellectual property and management expertise we have in the cannabis sector to become a leader in the distribution of medical cannabis products.

READ MORE


All Natural Foods

The team at Cann Global Ltd believe food is medicine, and a healthy lifestyle begins with a healthy plate. Within our health food division, we provide high-quality plant-based food, packed with nutrients, vitamins and minerals and we ensure all our products are chemical free and sustainably grown.

READ MORE


Cann Global Limited is an Australian public company listed on the Official List of the Australian Stock Exchange 

(ASX: CGB). The Company was admitted to the official list of ASX on 14 January 2008. (Previous ASX code: QBL)

Our Group comprises of 3 separate divisions:

Medical Cannabis Manufacturing – Medical Cannabis Research – All Natural Foods



The Group’s primary focus is to legally grow and cultivate hemp to research and develop medicinal cannabis products to service an increasing demand in the Australian and global markets.


Cann Global Ltd has a 100% shareholding in Medical Cannabis Ltd (MCL) and a management agreement with Medcan Australia Pty Ltd (Medcan) which operate a business cultivating, researching, developing and soon to be distributing medicinal cannabis products in Australia. Our Medical Cannabis division has been a key value driver for the Group.


The Group also retains an interest in its existing Bauxite Projects.


Our Mission

Within our Medical Cannabis division, we aim to be a growing force in cannabis research cultivation and the production of cannabinoid-based agents to develop, register, and commercialise pharmaceutical grade cannabinoid-therapies, products and treatments, to GMP quality standards.


We possess a lawful unique seedbank, developed and enhanced over the past 15 years in Australia. We are currently licensed to possess, cultivate, process, manufacture and supply Cannabis.


We will continue to investigate our seed bank, explore their genetics, cannabinoid ratios, terpene and volatile profiles and other chemical compounds produced by the Cannabis plant, to establish reliable chemovars for the medical research community.


Within our hemp food division, we aim to work together with the government in developing Trade and Industry standards, develop branding of National hemp foods Standards similar to what’s been done with the olive oil industry. We are working hard to create those standards, and to ensure Australian consumers don’t end up buying poor quality products under misleading labelling. 


We are creating a product we can be proud to sell because we have followed all the steps from farmers to plate to ensure that it is of the best quality and at the best price.


Our Knowledge

Andrew Kavasilas is recognised for pioneering work and his name is synonymous within the fledgling Australian hemp growing industry and medical Cannabis research.  Andrew is the founder and technical director of Medical Cannabis Ltd and Vitahemp Pty Ltd. 


His work in the hemp industry goes back two decades when he was growing industrial hemp under state permits back in 1999. He has been a strong advocate for cannabis law reform for years and he played an important role in the legalisation of hemp seed food.


Our Difference

The Group has two vertically integrated business from ‘seed to consumer’ in medicinal cannabis in addition to a fully vertically operated business in the nutritional hemp industry. Our two vertical integrations will effectively capture greater profits across the value chain.


Visit Cann Global's Website Here

(20min delay)
Last
0.5¢
Change
-0.001(9.09%)
Mkt cap ! $28.53M
Open High Low Value Volume
0.6¢ 0.6¢ 0.5¢ $17.47K 3.235M

Buyers (Bids)

No. Vol. Price($)
292 170644467 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 33485974 60
View Market Depth
Last trade - 16.10pm 27/07/2021 (20 minute delay) ?
(live)
Last
0.5¢
  Change
-0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 5465395
Last updated 15.56pm 27/07/2021 (live) ?
CGB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.